Daniel Dirkmann

TL;DR: First-line administration of coagulation factor concentrates combined with point-of-care testing was associated with decreased incidence of blood transfusion and thrombotic/thromboembolic events.

TL;DR: The implementation of perioperative POC coagulation management algorithms based on early, calculated, goaldirected therapy with fibrinogen concentrate and PCC is associated with a reduction in the transfusion requirements for FFP, PRBC and platelets as well as with a reduced incidence of massive transfusion.

TL;DR: Acidosis amplified the effects of hypothermia, and synergistically impaired clotting times, &agr; angle, and decreased maximum clot firmness, again in both extrinsically and intrinsically activated assays.

TL;DR: Early values of clot firmness allow for fast and reliable prediction of ROTEM(®) MCF in non-cardiac patients with subnormal, normal, and supranormal MCF values and therefore can be used to guide haemostatic therapy in severe bleeding.

TL;DR: The use of point-of-care transfusion and coagulation management algorithms guided by viscoelastic tests based on first-line therapy with fibrinogen and prothrombin complex concentrate have been associated with reduced allogeneic blood transfusion requirements, reduced incidence of thrombotic/thromboembolic and transfusion-related adverse events, and improved outcomes in cardiac surgery.